Does Presbyterian Healthcare Services Cover Wegovy?
The verdict
Conditional on most plans
Presbyterian Healthcare Services' Wegovy coverage for weight loss is employer-dependent and not publicly published in detail. As New Mexico's primary integrated health system insurer (commercial, Medicare, Medicaid), Presbyterian covers weight-loss GLP-1s only where the employer's plan design includes the anti-obesity benefit. New Mexico Centennial Care (Medicaid) weight-loss coverage is state-dependent and must be verified separately. Medicare Part D covers the cardiovascular indication only; the Medicare GLP-1 Bridge gives eligible beneficiaries weight-loss access at $50/month from July 1, 2026.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Presbyterian Healthcare Services using your member ID.
Key facts
Presbyterian Healthcare Services is New Mexico's primary integrated health system and insurer, serving commercial, Medicare, and Medicaid members; drug-level Wegovy coverage details are not publicly published.
Presbyterian Healthcare Services — phs.org
Medicare Part D cannot cover Wegovy for weight loss by statute; the Medicare GLP-1 Bridge ($50/month) launches July 1, 2026 for eligible beneficiaries outside Part D.
CMS.gov — Medicare GLP-1 Weight Loss Drug Access Program
Only 13 state Medicaid programs covered GLP-1s for obesity as of January 2026; New Mexico Centennial Care GLP-1 obesity coverage should be verified against the current preferred drug list.
KFF — Medicaid Coverage of and Spending on GLP-1 Medications
Medicare vs. commercial coverage
Whether Presbyterian Healthcare Services covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Presbyterian Healthcare Services Medicare Part D plans cannot cover Wegovy for weight loss by statute. The cardiovascular risk-reduction indication — for adults with established CVD who are overweight or obese — is coverable under Medicare with prior authorization. The Medicare GLP-1 Bridge, launching July 1, 2026 through December 31, 2027, gives eligible beneficiaries weight-loss access to Wegovy at $50/month outside the Part D benefit. The $50 copay does not count toward the $2,100 Part D OOP cap or TrOOP, and Extra Help cannot be applied. Bridge eligibility: BMI ≥35; or ≥30 with heart failure, uncontrolled hypertension, or CKD; or ≥27 with prediabetes, prior MI, prior stroke, or symptomatic PAD. Members already on a Part D-covered GLP-1 are ineligible. NovoCare savings card not available to Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
Presbyterian Healthcare Services commercial and employer plans cover Wegovy for weight loss only where the employer purchased the anti-obesity benefit. Presbyterian is New Mexico's largest integrated health system — its health plan serves commercial employer groups, state employee plans, Medicare, and Medicaid members across New Mexico. Drug-level Wegovy formulary detail is not publicly published, so coverage must be verified via the Presbyterian drug-lookup tool and confirmed with HR or your benefits administrator. Where the employer benefit exists, prior authorization with standard BMI and comorbidity criteria is expected. ACA/individual plans generally exclude weight-loss GLP-1s. Commercially insured members whose plan covers Wegovy may use the NovoCare savings card to pay as little as $25/month (max $100/28-day supply). Not available to Medicare or Medicaid beneficiaries. For New Mexico Centennial Care (Medicaid) members, weight-loss coverage for GLP-1s is state-dependent and should be verified against the current Centennial Care preferred drug list, as coverage for obesity drugs has shifted across states.
The 5 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 5 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price, 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period (through December 31, 2026).
List price with no coverage — before any manufacturer savings card.
With coverage
Plan-specific cost-share where the employer anti-obesity benefit is active — not publicly published. Use the Presbyterian drug-lookup tool with your member ID to confirm your tier and cost-share. Commercially insured members whose plan covers Wegovy may use the NovoCare savings card for as little as $25/month (max $100/28-day supply).
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month for eligible Medicare beneficiaries from July 1, 2026 through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap or TrOOP.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. Verify actual cost-share on the Presbyterian member portal or by calling member services before starting treatment. Novo Nordisk has announced list price reductions to approximately $675/month effective January 1, 2027.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Use the Presbyterian Healthcare Services drug-lookup tool
Visit phs.org and use the drug-lookup or formulary search tool with your member ID. Search for 'Wegovy' or 'semaglutide 2.4 mg' to confirm whether your specific plan includes the drug and what tier and PA requirements apply. Presbyterian does not publish drug-level Wegovy details outside the member portal.
- 2
Confirm with HR whether your employer's plan includes the anti-obesity benefit
Even if your plan type generally covers weight-loss GLP-1s, the benefit is only available if your employer purchased it. Ask HR or your benefits administrator directly. A benefit exclusion is a plan design decision and cannot be resolved through a prior-authorization submission.
- 3
Work with your prescriber on prior authorization
If the employer benefit is confirmed, your prescriber will document your BMI, qualifying comorbidities, and participation in a weight-management program. For Medicare members seeking the cardiovascular indication, confirm that established CVD is documented in your clinical record. For Medicaid members, verify the current New Mexico Centennial Care GLP-1 obesity coverage status with Presbyterian Centennial Care.
Options if Presbyterian Healthcare Services won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Medicare GLP-1 Bridge (Medicare members, from July 1, 2026)
Eligible Presbyterian Medicare members can access Wegovy for weight loss at $50/month through the Medicare GLP-1 Bridge starting July 1, 2026, operating outside Part D. Eligibility is based on BMI and clinical criteria; members already on a Part D-covered GLP-1 are ineligible.
NovoCare self-pay program
NovoCare Pharmacy offers Wegovy at approximately $349/month without insurance coverage. Introductory pricing applies through December 31, 2026. Novo Nordisk has announced list price reductions to approximately $675/month effective January 1, 2027.
Compounded semaglutide
Compounded semaglutide is available without insurance. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Presbyterian Healthcare Services covers Wegovy for weight loss only on commercial and employer plans where the employer purchased the anti-obesity benefit. The plan does not publish drug-level Wegovy formulary detail, so you must use the Presbyterian drug-lookup tool and confirm with HR. ACA/individual plans generally exclude weight-loss GLP-1s. Where the benefit exists, prior authorization is required with BMI documentation, lifestyle program participation, and ongoing weight-loss progress for renewal.
New Mexico Centennial Care weight-loss coverage for GLP-1s is state-dependent and subject to change. As of January 2026, only 13 state Medicaid programs covered GLP-1s for obesity, and coverage has shifted across states during 2025–2026. Presbyterian Centennial Care members should verify the current New Mexico Medicaid preferred drug list for GLP-1 obesity coverage directly with Presbyterian or through the New Mexico Human Services Department. Non-weight-loss FDA indications for Wegovy remain coverable where applicable.
Presbyterian Medicare Part D plans cannot cover Wegovy for weight loss by statute. The cardiovascular risk-reduction indication is coverable with prior authorization for members with established CVD who are overweight or obese. Starting July 1, 2026, eligible Medicare members can access Wegovy for weight loss at $50/month through the Medicare GLP-1 Bridge, which operates outside Part D and does not count toward the $2,100 OOP cap. Verify PA criteria on the Presbyterian Medicare plan drug list.
Like other integrated-system regional plans (such as Security Health Plan in Wisconsin or Geisinger in Pennsylvania), Presbyterian does not publish drug-level Wegovy formulary specifics, making employer opt-in verification and the drug-lookup tool essential first steps. The distinguishing factor is New Mexico context: Centennial Care (Medicaid) is the state-specific Medicaid program to verify, and Presbyterian operates as the dominant integrated system insurer statewide — which means your employer may have a Presbyterian group plan even in a non-major-metro setting in New Mexico.
Commercially insured Presbyterian members whose plan covers Wegovy can use the NovoCare savings card to pay as little as $25/month (max $100 savings per 28-day supply). The card is not available to Medicare or Medicaid beneficiaries under federal anti-kickback rules. If your Presbyterian plan does not cover Wegovy, the NovoCare self-pay option (approximately $349/month) is available regardless of coverage status.
Related Articles
Does BCBS North Carolina Cover Wegovy? 2026 | Curex
BCBS North Carolina: NC State Health Plan dropped weight-loss GLP-1s in 2024; NC Medicaid removed obesity coverage October 2025. Verify your specific plan.
Read moreDoes BCBS of Arizona Cover Wegovy? 2026 Guide | Curex
BCBS of Arizona covers Wegovy only where your employer opted in; formulary not published. Verify via drug-lookup and confirm with HR first.
Read moreDoes Blue Cross Blue Shield Cover Wegovy? 2026 | Curex
BCBS is 33+ independent affiliates — no single Wegovy answer. Trend favors exclusion in 2025-2026. Find your affiliate and verify your formulary.
Read moreDoes Blue Cross Blue Shield of Illinois Cover Wegovy? | Curex
BCBS Illinois (HCSC) covers Wegovy only where your employer opts in. ACA plans exclude it. Formulary not public — verify on your plan's drug-lookup tool.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Presbyterian Healthcare Services Cover Mounjaro? | Curex
Presbyterian (NM) covers Mounjaro for type 2 diabetes with PA — not weight loss. NM Medicaid covers some weight-loss GLP-1s, but not Mounjaro.
Read moreWhether or not Presbyterian Healthcare Services covers Wegovy, there's a path that skips insurance
Presbyterian covers Wegovy for weight loss only where the employer opted in. For patients without that benefit, Curex offers compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Presbyterian Healthcare Services before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.